Oncolytics Biotech® Inc. i aso nei na faʻasalalau le lolomiina o faʻamatalaga faʻapitoa ma faʻamaʻi i luga o le pelareorep i totonu o le tusi talaaga a le tupulaga Immunology. O le pepa, ua faaulutalaina "Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity," na lomia faʻatasi ma tagata suʻesuʻe i le tele o faʻalapotopotoga faʻapitoa, e aofia ai le Iunivesite o Leeds School of Medicine ma le Institute of Cancer Research, Lonetona. E mafai ona maua se feso'ota'iga ile pepa ile kiliki iinei.
O loʻo faʻamatalaina i totonu o le pepa o suʻesuʻega in vitro e suʻesuʻeina ai aʻafiaga o le pelareorep i luga o sela Natural Killer (NK) faʻapea foʻi ma suʻesuʻega o faʻataʻitaʻiga toto mai tagata mamaʻi e maua i le ate colorectal metastases aʻo leʻi faia ma pe a maeʻa togafitiga ma le pelareorep. I'uga na fa'aalia ai le togafitiga o le pelareorep na ta'ita'ia ai le fa'agaoioia o sela NK, lea e iloa e fa'amaoti sa'o ai sela o le kanesa a'o fa'aosofia ai le fa'aogaina o le puipuiga o le tumor. O aʻafiaga aoga o le pelareorep na matauina uma i faʻataʻitaʻiga maʻi ma in vitro ma faʻatalanoaina e le ituaiga 1 interferon (IFN-1) faʻailoga, o se auala autu e aʻafia i le immunoregulation ma le iloa o le tumo.
“O nei fa'ai'uga taua ua fa'aalia atili ai le fa'aogaina o le tino ma le adaptive immunologic mechanism o le pelareorep, ma matou te fiafia e fa'asalalauina i totonu o se tusi talaaga fa'apitoa, su'esu'eina e tupulaga," o le tala lea a Dr. Matt Coffey, Peresetene ma le Ofisa Sili o Pulega o Oncolytics Biotech ma tusitala o le pepa. "Pe a vaʻavaʻai i nei suʻesuʻega, faʻatasi ai ma faʻamaumauga muamua a le falemaʻi o loʻo faʻaalia ai le malosi o le pelareorep e faʻagaoioia ai sela T aʻo faʻalauiloaina lo latou faʻaulu i totonu o le tuma, matou te vaʻai i le pelareorep o loʻo tuʻuina atu se malosi, faʻamaopoopoina faʻamaʻi faʻamaʻi faʻamaʻi pipisi e taʻitaʻia e le faʻaogaina ma le faʻaogaina o le puipuiga. I le vaʻavaʻai atu i luma, o le a faʻaauau pea ona matou faʻaogaina le immunotherapeutic aʻafiaga o le pelareorep aʻo matou faʻalauteleina lona atinaʻe e avea o se tekonolosi faʻamalosia mo le lautele o vaega o immunotherapeutic agents i le kanesa o le susu ma isi faʻailoga oncologic e maualuga manaʻoga e leʻi ausia.
O fa'ata'ita'iga o tagata ma'i na iloiloina i totonu o le fa'asalalauga na maua mai i su'esu'ega fa'ama'i fa'ama'i fa'amalama o avanoa e iloilo ai le pelareorep i tagata mama'i kanesa colorectal ma metastases o le ate. O tagata ma'i na maua i le va o le tasi ma le lima tui o le pelareorep a'o le'i faia le taotoga fuafuaina e fa'amama ai metastases. O faʻataʻitaʻiga toto na faia uma aʻo leʻi faia ma i le tele o taimi pe a maeʻa togafitiga o le pelareorep. O fa'amatalaga fa'aopoopo o le fa'amasinoga, fa'apea fo'i ma fa'ai'uga na lipotia muamua, o lo'o maua i fa'asalalauga muamua a tupulaga.
OA MEA E AVEA MAI LENEI TUSI:
- Described in the paper are in vitro studies evaluating pelareorep’s effects on Natural Killer (NK) cells as well as analyses of blood samples from patients with colorectal liver metastases taken prior to and after treatment with pelareorep.
- The beneficial effects of pelareorep were observed both in patient samples and in vitro and were mediated by type 1 interferon (IFN-1) signaling, a key pathway involved in immunoregulation and tumor cell recognition.
- Looking forward, we will continue to leverage the immunotherapeutic effects of pelareorep as we further its development as an enabling technology for a wide cross-section of immunotherapeutic agents in breast cancer and other oncologic indications with high unmet needs.
